logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2018—French study shows mFOLFIRINOX extends life in patients with resected pancreatic cancer compared with gemcitabine

Patients with pancreatic ductal adenocarcinoma lived a median of 20 months longer.